<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	line-height:107%;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;
	font-weight:normal;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	line-height:107%;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#1F3763;
	font-weight:normal;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Calibri Light",sans-serif;
	color:#2F5496;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Calibri Light",sans-serif;
	color:#1F3763;}
.MsoChpDefault
	{font-family:"Calibri",sans-serif;}
.MsoPapDefault
	{margin-bottom:8.0pt;
	line-height:107%;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-GB>

<div class=WordSection1>

<h1><span lang=EN-US style='font-size:15.0pt;line-height:107%'>2014A02 Draw and
explain the characteristics of a log dose response curve that describes the
major clinical effect of rocuronium. Describe how factors encountered in
clinical practice may alter this curve.</span></h1>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US style='font-size:13.0pt;line-height:107%'>List:</span></h3>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:22.5pt;margin-bottom:.0001pt;text-indent:-13.5pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Graph</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:22.5pt;margin-bottom:.0001pt;text-indent:-13.5pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Intro</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:22.5pt;margin-bottom:.0001pt;text-indent:-13.5pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Factors &#8593;ED<sub>95</sub> = R shift =
&#8595;potency</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:22.5pt;margin-bottom:.0001pt;text-indent:-13.5pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Factors &#8595;ED<sub>95</sub> = L shift =
&#8593;potency</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:22.5pt;margin-bottom:.0001pt;text-indent:-13.5pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Factors &#8593;duration (not relevant here)</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US style='font-size:13.0pt;line-height:107%'>Graph:</span></h3>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>Population, quantal curve</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US><img width=258 height=215 id="Picture 2"
src="2014A02_non_depolarising_relaxants_log_dose_response_curve_files/image001.jpg"></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US style='font-size:13.0pt;line-height:107%'>Intro:</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Rocuronium</span></p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Non-depolarising relaxant</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Competitive inhibitor at </span><span lang=EN-US>&#945;</span><span
  lang=EN-US>-subunit of nAChR at NMJ</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Must bind 70% of receptors before significant effect due to spare
  receptors</span></p>
  </td>
 </tr>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Measured responses</span></p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Onset time (time to 95% &#8595;single twitch height)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Depth (minimum post-tetanic count?)</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Offset time (time to TOF ratio 0.9)</span></p>
  </td>
 </tr>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Muscle group differences</span></p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US> Laryngeal muscle cf. adductor pollicis:</span></p>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Physiological differences:</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:30.55pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US>&#8593;Blood
  flow</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:30.55pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US>&#8593;ACh
  vesicle release</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:30.55pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US>&#8593;ACh
  receptors</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Clinical implication:</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:30.55pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US>Faster
  onset</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:30.55pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US>Less
  depth</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:30.55pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:"Courier New"'>o<span
  style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US>Shorter
  duration</span></p>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><img width=215 height=174 id="Picture 3"
  src="2014A02_non_depolarising_relaxants_log_dose_response_curve_files/image002.jpg"></p>
  </td>
 </tr>
 <tr>
  <td width=108 valign=top style='width:80.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Implications of inter-individual differences</span></p>
  </td>
  <td width=493 valign=top style='width:370.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>&#8593;Potency and &#8593;duration: failure of reversal -&gt;
  distress, T2RF, aspiration</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>&#8595;Duration: movement when dangerous e.g. neurosurgery</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Twitch monitoring essential whenever relaxants used</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US style='font-size:13.0pt;line-height:107%'>Factors
&#8593;ED<sub>95</sub> = R shift = &#8595;potency:</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=84 valign=top style='width:62.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Physiology</span></p>
  </td>
  <td width=517 valign=top style='width:388.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;line-height:
  normal'><span lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>&#8593;K<sup>+</sup>: membrane
  depolarisation-&gt; &#8593;ACh release -&gt; &#8595;drug:ACh ratio</span></p>
  </td>
 </tr>
 <tr>
  <td width=84 valign=top style='width:62.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Pathology</span></p>
  </td>
  <td width=517 valign=top style='width:388.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Critical illness myopathy, burns -&gt; proliferation of
  extrajunctional receptors -&gt; &#8595;drug:ACh atio</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Malignant hyperthermia-&gt; post-junctional activation</span></p>
  </td>
 </tr>
 <tr>
  <td width=84 valign=top style='width:62.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Competitive reversal</span></p>
  </td>
  <td width=517 valign=top style='width:388.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;line-height:
  normal'><span lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>AChEi e.g. neostigmine: &#8595;drug:ACh ratio</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
  margin-left:3.35pt;margin-bottom:.0001pt;line-height:normal'><span
  lang=EN-US>(g-cyclodextrin chelates rocuronium in plasma, increases the
  gradient between effect site and plasma but does not alter the dose-response
  curve)</span></p>
  </td>
 </tr>
 <tr>
  <td width=84 valign=top style='width:62.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Toxins</span></p>
  </td>
  <td width=517 valign=top style='width:388.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;line-height:
  normal'><span lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Tetanus toxin: &#8595;inhibition of a-motor
  neurons -&gt; &#8593;NMJ activity -&gt; &#8595;drug:ACh ratio</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<h3><span lang=EN-US style='font-size:13.0pt;line-height:107%'>Factors
&#8595;ED<sub>95</sub> = L shift = &#8593;potency</span></h3>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=84 valign=top style='width:62.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Physiology</span></p>
  </td>
  <td width=517 valign=top style='width:388.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>&#8595;ACh release -&gt; &#8593;drug:ACh ratio</span></p>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Neonate: immature NMJ</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Respiratory acidosis</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>&#8593;Mg<sup>2+</sup>: &#8593;competition with Ca<sup>2+</sup></span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>&#8595;K<sup>+</sup>: membrane potential more negative -&#8595;ACh
  release</span></p>
  </td>
 </tr>
 <tr>
  <td width=84 valign=top style='width:62.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Pathology</span></p>
  </td>
  <td width=517 valign=top style='width:388.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Myasthaenia gravis: antibody against NMJ nAChR -&gt; &#8593;drug:receptor
  ratio</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Lambert-Eaton syndrome: antibody against pre-synaptic VDCC -&gt;
  &#8595;competition with ACh</span></p>
  </td>
 </tr>
 <tr>
  <td width=84 valign=top style='width:62.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Pre-synaptic drugs</span></p>
  </td>
  <td width=517 valign=top style='width:388.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>&#8595;ACh release -&gt; &#8593;drug: ACh ratio</span></p>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>&#8595;</span><span lang=EN-US>&#945;</span><span lang=EN-US>-motor
  neuron activity: volatile anaesthetic</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>&#8595; axonal action potential: peripheral nerve local anaesthetic
  (&#8595;Na<sup>+</sup> flux)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>&#8595;Choline uptake: hemicholinium</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>&#8595;ACh transport into vesicles: vesamicol</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>&#8595;AMP/ATP synthesis (frusemide)</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Block pre-synaptic nAChR (volatiles)</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Block L-Ca<sup>2+</sup> (CCB, Mg<sup>2+</sup>, aminoglycosides,
  volatiles)</span></p>
  </td>
 </tr>
 <tr>
  <td width=84 valign=top style='width:62.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Post-synaptic drugs</span></p>
  </td>
  <td width=517 valign=top style='width:388.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>&#8595;Ion flux through nAChR</span></p>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Block post-synaptic nAChR: other non-depolarisers, volatiles,
  aminoglycoside, quinidine</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Desensitisation blockade (volatiles, barbiturates)</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Inhibit peri-junctional action potential: local anaesthetic
  &#8595;Na<sup>+</sup> flux</span></p>
  </td>
 </tr>
 <tr>
  <td width=84 valign=top style='width:62.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Post-junctional drugs</span></p>
  </td>
  <td width=517 valign=top style='width:388.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
  0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;line-height:
  normal'><span lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
  </span></span><span lang=EN-US>Dantrolene: inhibit skeletal muscle ryanodine
  receptor</span></p>
  </td>
 </tr>
 <tr>
  <td width=84 valign=top style='width:62.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Toxins</span></p>
  </td>
  <td width=517 valign=top style='width:388.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Botox: cleave SNARE protein, &#8595;ACh release</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Tetrodotoxin: VDNaC inhibition</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<h1><span lang=EN-US style='font-size:15.0pt;line-height:107%'>Addit: factors
increasing duration</span></h1>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><i><span
lang=EN-US>*All those causing &#8593;potency plus*</span></i></p>

<table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=84 valign=top style='width:62.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Pathology</span></p>
  </td>
  <td width=517 valign=top style='width:388.05pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>&#8595;Temp: &#8595;rate of Hoffman degradation and ester
  hydrolysis</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>&#8593;pH: &#8595;rate of ester hydrolysis</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>&#8595;pH: &#8595;rate of Hofmann degradation</span></p>
  <p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Atracurium: 60% ester hydrolysis, 30%, Hoffman elimination, 10% in
  urine unchanged</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Cisatracurium: 80% Hoffman elimination, 15% ester hydrolysis, 5%
  in urine unchanged</span></p>
  </td>
 </tr>
 <tr>
  <td width=84 valign=top style='width:62.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
  normal'><span lang=EN-US>Pathology</span></p>
  </td>
  <td width=517 valign=top style='width:388.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Liver failure: accumulation of bile eliminated drug (e.g.
  vecuronium 70%)</span></p>
  <p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
  margin-bottom:0in;margin-left:12.35pt;margin-bottom:.0001pt;text-indent:-9.0pt;
  line-height:normal'><span lang=EN-US style='font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span><span
  lang=EN-US>Renal failure: accumulation of drug (e.g. gallamine 100% renal),
  metabolite (e.g. 3-OH-panc 50% potency)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt'><span
lang=EN-US>&nbsp;</span></p>

</div>

</body>

</html>
